
Supplementary Material


Supplementary Figure S1

EFS and OS of 190 study group patients with *MYCN* amplification by stage (1, 2, 3, 4S vs. stage 4 aged <18 months)




Supplementary Figure S2

EFS and OS of 185 study group patients by stage and best result of surgical resection



Supplementary Figure S3

EFS and OS of 87 study group patients by independent risk factors 'presence of mutation' (mutation vs. no mutation) and 'best result of surgical resection'* (no/incomplete/biopsy vs. complete)



*If more than one surgical intervention, the best result was counted. Pairwise comparisons (Log-rank p-values, Bonferroni-Holm adjusted) EFS:

No/incomplete/biopsy, no mutation vs. Complete, no mutation: 0.059 No/incomplete/biopsy, no mutation vs. No/incomplete/biopsy, mutation: 0.059 No/incomplete/biopsy, no mutation vs. Complete, mutation: N.A. (curves cross) Complete, no mutation vs. No/incomplete/biopsy, mutation: < 0.001 Complete, no mutation vs. Complete, mutation: 0.057 No/incomplete/biopsy, mutation vs. Complete, mutation: 0.155

OS:

No/incomplete/biopsy, no mutation vs. Complete, no mutation: 0.002 No/incomplete/biopsy, no mutation vs. No/incomplete/biopsy, mutation: 0.065 No/incomplete/biopsy, no mutation vs. Complete, mutation: N.A. (curves cross) Complete, no mutation vs. No/incomplete/biopsy, mutation: < 0.001 Complete, no mutation vs. Complete, mutation: 0.001 No/incomplete/biopsy, mutation vs. Complete, mutation: 0.164